Extrait

Background and study aims Dry socket is a common complication that can arise following the extraction of teeth by a dentist (General Dental Practitioner) or a specialist (Oral Surgery Specialist). Dry socket may be defined as the postoperative pain inside and around an extraction site, which increases in severity at any time between the first and third day after the extraction, accompanied by a partial or total disintegration of the blood clot within the tooth socket, with or without smelly breath (halitosis). Sufferers of dry socket usually need postoperative treatment to manage the condition. The routine treatment for dry socket involves cleaning the area, under anaesthetic if necessary, packing it with a material to soothe the pain and if necessary using a suture (stitch) to hold the material in place while the socket heals. The material used to pack the socket plays an important role in soothing the pain and allowing healing to take place and researchers are always trying to find better more effective materials. A new material that can help the healing of tissue in the mouth following surgery is a product derived from the patients' own blood called PRGF (Plasma Rich in Growth Factors). It has been shown that PRGF enhances tissue healing and also improves the clinical outcomes of various surgical procedures by minimizing postoperative complications such as pain and inflammation/swelling. Venous blood is taken from the patient prior to surgery. The blood is then treated and heated to form a gel like structure which is then inserted at the treatment site. The PRGF then acts on the surrounding tissues to aid healing and regeneration. The aim of this study is to investigate whether PRGF can reduce the pain and improve the healing of dry sockets in patients who have this condition following the extraction of a tooth when compared with a conventional treatment, Alvogyl®. Who can participate? Adult dental patients of either gender who have been diagnosed with a dry tooth socket that requires treatment. What does the study involve? Patients will be randomly allocated to one of two treatment possibilities: either the use of conventional treatment of Alvogyl® or the use of PRGF. What are the possible benefits and risks of participating? While we cannot be sure that the PRGF will improve clinical outcome, previous studies in which PRGF has been used in other oral surgery procedures, such as implant placement, have shown to be beneficial in reducing inflammation and healing times. The risks in taking part are no greater than those a participant would be exposed to during standard treatment, with some pain or discomfort likely, but normal for this type of procedure. Where is the study run from? One single centre, Bristol Dental Hospital (UK) When is the study starting and how long is it expected to run for? November 2014 to March 2015 Who is funding the study? University of Bristol (UK) Who is the main contact? Professor Nicola West

Critère d'inclusion

• Dry socket or alveolar osteitis

Liens

• isrctn
• ictrp